Citadel Advisors
BCLI

Citadel Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Citadel Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,730
Closed -$62.1K – 14286
2023
Q2 		$84.4K Buy
2,730
+1,852
+211% +$76.7K ﹤0.01% 11178
2023
Q1 		$43.5K Sell
878
-220
-20% -$6.38K ﹤0.01% 12345
2022
Q4 		$27K Sell
1,098
-969
-47% -$36.2K ﹤0.01% 12868
2022
Q3 		$137K Buy
2,067
+355
+21% +$17.8K ﹤0.01% 10806
2022
Q2 		$70K Buy
1,712
+104
+6% +$4.68K ﹤0.01% 11703
2022
Q1 		$81K Buy
+1,608
New +$78.9K ﹤0.01% 12470
2021
Q4 		– Sell
-1,099
Closed -$54.1K – 13793
2021
Q3 		$54K Sell
1,099
-2,312
-68% -$122K ﹤0.01% 13330
2021
Q2 		$195K Buy
3,411
+774
+29% +$41.4K ﹤0.01% 12185
2021
Q1 		$151K Buy
+2,637
New +$199K ﹤0.01% 12020
2020
Q1 		– Sell
-816
Closed -$63.7K – 9573
2019
Q4 		$52K Buy
+816
New +$47.3K ﹤0.01% 8743
2019
Q3 		– Sell
-1,121
Closed -$66K – 9149
2019
Q2 		$66K Buy
1,121
+194
+21% +$11.3K ﹤0.01% 8657
2019
Q1 		$60K Buy
927
+203
+28% +$11.5K ﹤0.01% 8753
2018
Q4 		$39K Buy
+724
New +$35.7K ﹤0.01% 8546
2018
Q1 		– Sell
-1,002
Closed -$59K – 8262
2017
Q4 		$59K Buy
1,002
+15
+2% +$897 ﹤0.01% 7582
2017
Q3 		$61K Buy
+987
New +$63.9K ﹤0.01% 7144
2017
Q2 		– Sell
-1,158
Closed -$71.4K – 7468
2017
Q1 		$74K Buy
+1,158
New +$60.3K ﹤0.01% 6952
2016
Q2 		– Sell
-797
Closed -$32K – 6816
2016
Q1 		$32K Buy
+797
New +$29.3K ﹤0.01% 6361

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BCLI Position: Q3 2023 in Review

Citadel Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 2,730 shares — an estimated $62.1K sold.

Citadel Advisors first reported a position in BCLI in Q1 2016 and held it in 17 quarters. The position peaked at $195K in Q2 2021. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Citadel Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 2,730 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $62.1K.
  • Citadel Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 17 quarters.
  • Citadel Advisors's BRAINSTORM CELL THERAPUTC position peaked at $195K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.